The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

• DOI: 10.1523/jneurosci.5218-14.2015
• Publication Date: 2015-04-22T16:29:41Z
• Authors: Faith H. Brennan; Richard Gordon; Hong W. Lao; Patrick J. Biggins; Stephen M. Taylor; Robin J.M. Franklin; Trent M. Woodruff; Marc J. Ruitenberg
• Keywords: 2800 Neuroscience; 572; Macrophage; Complement C5a; Motor Activity; Anaphylatoxin; Peptides, Cyclic; Mice; 03 medical and health sciences; Oligodendrocyte precursor cell; Animals; CNS trauma; Gliosis; Complement Activation; Receptor, Anaphylatoxin C5a; Cells, Cultured; Spinal Cord Injuries; Cell Proliferation; Inflammation; Mice, Knockout; 0303 health sciences; Recovery of Function; Astrocytes; Demyelinating pathology; Female; Secondary degeneration

This study investigated the role of the complement activation fragment C5a in secondary pathology following contusive spinal cord injury (SCI).C5ar−/−mice, which lack the signaling receptor for C5a, displayed signs of improved locomotor recovery and reduced inflammation during the first week of SCI compared with wild-type mice. Intriguingly, the early signs of improved recovery inC5ar−/−mice deteriorated from day 14 onward, with absence of C5aR ultimately leading to poorer functional outcomes, larger lesion volumes, reduced myelin content, and more widespread inflammation at 35 d SCI. Pharmacological blockade of C5aR with a selective antagonist (C5aR-A) during the first 7 d after SCI improved recovery compared with vehicle-treated mice, and this phenotype was sustained up to 35 d after injury. Consistent with observations made inC5ar−/−mice, these improvements were, however, lost if C5aR-A administration was continued into the more chronic phase of SCI. Signaling through the C5a-C5aR axis thus appears injurious in the acute period but serves a protective and/or reparative role in the post-acute phase of SCI. Further experiments in bone marrow chimeric mice suggested that the dual and opposing roles of C5aR on SCI outcomes primarily relate to its expression on CNS-resident cells and not infiltrating leukocytes. Additionalin vivoandin vitrostudies provided direct evidence that C5aR signaling is required during the postacute phase for astrocyte hyperplasia, hypertrophy, and glial scar formation. Collectively, these findings highlight the complexity of the inflammatory response to SCI and emphasize the importance of optimizing the timing of therapeutic interventions.